The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope (2024)
Journal Article
Mercer, L., Abhishek, A., Kavirayani, A., Ahmed, A., Davidson, A., Foulkes, A., …Galloway, J. (in press). The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 8(3), Article rkae077. https://doi.org/10.1093/rap/rkae077

Lay Summary: What does this mean for patients? A revised guideline, produced by the British Society for Rheumatology (BSR), will provide up-to-date information about the safe prescribing and monitoring of the effects of non-biologic (or conventional... Read More about The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug (2024)
Journal Article
Porter, J., Noble, A. R., Signoret, N., Fascione, M. A., & Miller, G. J. (in press). Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug. ACS Omega, 9(29), 31703-31713. https://doi.org/10.1021/acsomega.4c02417

Nucleoside analogues are established treatments for cancer and viral infection. Gemcitabine is a commonly employed nucleoside analogue displaying anticancer properties against a range of tumor types but is rapidly inactivated in vivo. Efforts to bols... Read More about Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug.